高盛深度解读：康诺亚生物如何布局免疫学“双引擎”，核心产品Stapokibart商业化与创新双抗CM512的增长潜力分析

Open in Podwise to generate AI notes

Sign in to process this episode and unlock summaries, transcripts, highlights and translations.